Cargando…

Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges

Cancer immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized oncology. However, only a limited number of patients benefit from immunotherapy, and some cancers that initially respond to immunotherapy can ultimately relapse and progress. Thus, some studies have investigated co...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shu‐Jin, Chen, Jia‐Xian, Sun, Zhi‐Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441058/
https://www.ncbi.nlm.nih.gov/pubmed/34137513
http://dx.doi.org/10.1002/cac2.12183